{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:11:24Z","timestamp":1772752284292,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1245\/s10434-010-0975-6","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T17:48:48Z","timestamp":1271699328000},"page":"1247-1256","source":"Crossref","is-referenced-by-count":45,"title":["Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?"],"prefix":"10.1245","volume":"17","author":[{"given":"Andrew X.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"975_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"975_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000173419","volume":"75","author":"SR Kim","year":"2008","unstructured":"Kim SR, Kudo M, Hino O, et al. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology. 2008;75(Suppl 1):13\u20136.","journal-title":"Oncology"},{"key":"975_CR3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","volume":"27","author":"SF Altekruse","year":"2009","unstructured":"Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485\u201391.","journal-title":"J Clin Oncol"},{"key":"975_CR4","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557\u201376.","journal-title":"Gastroenterology"},{"key":"975_CR5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1634\/theoncologist.11-7-790","volume":"11","author":"AX Zhu","year":"2006","unstructured":"Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11:790\u2013800.","journal-title":"Oncologist"},{"key":"975_CR6","first-page":"73","volume":"22","author":"C Clavi\u00e8re","year":"1998","unstructured":"Clavi\u00e8re C, Bronowicki JP, Hudziak H, Bigard MA, Gaucher P. Roles of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma. Gastroneterol Clin Biol. 1998;22:73\u201386.","journal-title":"Gastroneterol Clin Biol"},{"key":"975_CR7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hep.1840090417","volume":"9","author":"A Francavilla","year":"1989","unstructured":"Francavilla A, Polimeno L, DiLeo A, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology. 1989;9:614\u201320.","journal-title":"Hepatology"},{"key":"975_CR8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/0168-8278(95)80038-7","volume":"23","author":"SY Jiang","year":"1995","unstructured":"Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol. 1995;23:712\u20139.","journal-title":"J Hepatol"},{"key":"975_CR9","doi-asserted-by":"crossref","unstructured":"Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet. 1998;352:17\u201320.","DOI":"10.1016\/S0140-6736(98)01259-8"},{"key":"975_CR10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","volume":"36","author":"PK Chow","year":"2002","unstructured":"Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002;36:1221\u20136.","journal-title":"Hepatology"},{"key":"975_CR11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1572-0241.2000.01688.x","volume":"95","author":"CL Liu","year":"2000","unstructured":"Liu CL, Fan ST, Ng IO, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95:218\u201322.","journal-title":"Am J Gastroenterol"},{"key":"975_CR12","first-page":"1535","volume":"21","author":"EK Manesis","year":"1995","unstructured":"Manesis EK, Giannoulis G, Zoumboulis P, et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 1995;21:1535\u201342.","journal-title":"Hepatology"},{"key":"975_CR13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004836-199804000-00010","volume":"26","author":"S Riestra","year":"1998","unstructured":"Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol. 1998;26:200\u20133.","journal-title":"J Clin Gastroenterol"},{"key":"975_CR14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.1998.16.2.411","volume":"16","author":"C Grimaldi","year":"1998","unstructured":"Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998;16:411\u20137.","journal-title":"J Clin Oncol"},{"key":"975_CR15","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O","volume":"56","author":"E Sciarrino","year":"1985","unstructured":"Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer. 1985;56:2751\u20135.","journal-title":"Cancer"},{"key":"975_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(88)90007-2","volume":"15","author":"SR Nerenstone","year":"1988","unstructured":"Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev. 1988;15:1\u201331.","journal-title":"Cancer Treat Rev"},{"key":"975_CR17","first-page":"1676","volume":"5","author":"TW Leung","year":"1999","unstructured":"Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5:1676\u201381.","journal-title":"Clin Cancer Res"},{"key":"975_CR18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","volume":"97","author":"W Yeo","year":"2005","unstructured":"Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"975_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3835(98)00280-8","volume":"135","author":"M Huang","year":"1999","unstructured":"Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999;135:97\u2013105.","journal-title":"Cancer Lett"},{"key":"975_CR20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jso.1129","volume":"78","author":"A Kato","year":"2001","unstructured":"Kato A, Miyazaki M, Ambiru S, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol. 2001;78:110\u20135.","journal-title":"J Surg Oncol"},{"key":"975_CR21","first-page":"531","volume":"3","author":"MT Kuo","year":"1992","unstructured":"Kuo MT, Zhao JY, Teeter LD, et al. Activation of multidrug resistance (P-glycoprotein) mdr3\/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ. 1992;3:531\u201340.","journal-title":"Cell Growth Differ"},{"key":"975_CR22","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"975_CR23","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138.","journal-title":"Cancer Res"},{"key":"975_CR24","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293\u2013300.","journal-title":"J Clin Oncol"},{"key":"975_CR25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"975_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"975_CR27","unstructured":"Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S\u00a0+\u00a0D) versus placebo plus doxorubicin (P\u00a0+\u00a0D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) (abstract 128), Orlando, FL. Presented at 2008 gastrointestinal cancers symposium."},{"key":"975_CR28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/jcp.2003.015784","volume":"57","author":"L Messerini","year":"2004","unstructured":"Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol. 2004;57:867\u201371.","journal-title":"J Clin Pathol"},{"key":"975_CR29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0168-8278(97)80323-6","volume":"27","author":"H Miura","year":"1997","unstructured":"Miura H, Miyazaki T, Kuroda M, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997;27:854\u201361.","journal-title":"J Hepatol"},{"key":"975_CR30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.510280111","volume":"28","author":"R Yamaguchi","year":"1998","unstructured":"Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68\u201377.","journal-title":"Hepatology"},{"key":"975_CR31","first-page":"725","volume":"7","author":"R Yamaguchi","year":"2000","unstructured":"Yamaguchi R, Yano H, Nakashima Y, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 2000;7:725\u20139.","journal-title":"Oncol Rep"},{"key":"975_CR32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1245\/ASO.2003.10.002","volume":"10","author":"Y Chao","year":"2003","unstructured":"Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003;10:355\u201362.","journal-title":"Ann Surg Oncol"},{"key":"975_CR33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3748\/wjg.v10.i5.643","volume":"10","author":"KS Jeng","year":"2004","unstructured":"Jeng KS, Sheen IS, Wang YC, et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 2004;10:643\u20138.","journal-title":"World J Gastroenterol"},{"key":"975_CR34","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bjs.4594","volume":"91","author":"RT Poon","year":"2004","unstructured":"Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354\u201360.","journal-title":"Br J Surg"},{"key":"975_CR35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"975_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145\u20137.","journal-title":"Nat Med"},{"key":"975_CR37","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","volume":"26","author":"AB Siegel","year":"2008","unstructured":"Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992\u20138.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR38","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/jco.2007.25.18_suppl.4570","volume":"25","author":"D Malka","year":"2007","unstructured":"Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol. 2007;25(Suppl):4570.","journal-title":"J Clin Oncol"},{"key":"975_CR39","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","volume":"24","author":"AX Zhu","year":"2006","unstructured":"Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898\u2013903.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR40","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/jco.2007.25.18_suppl.4574","volume":"25","author":"W Sun","year":"2007","unstructured":"Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol. 2007;25(Suppl):4574.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR41","doi-asserted-by":"crossref","first-page":"15190","DOI":"10.1200\/jco.2007.25.18_suppl.15190","volume":"25","author":"C Hsu","year":"2007","unstructured":"Hsu C, Yang T, Hsu C, et al. Modified-dose capecitabine\u00a0+\u00a0bevacizumab for the treatment of advanced\/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. J Clin Oncol. 2007;25(Suppl):15190.","journal-title":"J Clin Oncol"},{"key":"975_CR42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","volume":"27","author":"MB Thomas","year":"2009","unstructured":"Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843\u201350.","journal-title":"J Clin Oncol"},{"key":"975_CR43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"975_CR44","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327\u201337.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"975_CR45","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(02)80597-4","volume":"38","author":"T Pawson","year":"2002","unstructured":"Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;38(Suppl 5):S3\u201310.","journal-title":"Eur J Cancer"},{"key":"975_CR46","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","volume":"27","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027\u201335.","journal-title":"J Clin Oncol"},{"key":"975_CR47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","volume":"10","author":"S Faivre","year":"2009","unstructured":"Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10:794\u2013800.","journal-title":"Lancet Oncol"},{"key":"975_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2008.02.022","volume":"49","author":"H Huynh","year":"2008","unstructured":"Huynh H, Chow PK, Palanisamy N, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 2008;49:52\u201360.","journal-title":"J Hepatol"},{"issue":"Suppl","key":"975_CR49","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/jco.2009.27.15_suppl.4577","volume":"27","author":"JL Raoul","year":"2009","unstructured":"Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(Suppl):4577.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR50","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/jco.2009.27.15_suppl.4581","volume":"27","author":"H Toh","year":"2009","unstructured":"Toh H, Chen P, Carr BI, et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol. 2009;27(Suppl):4581.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR51","first-page":"3561","volume":"27","author":"CC Yau","year":"2009","unstructured":"Yau CC, Chen PJ, Curtis CM, et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(Suppl):3561.","journal-title":"J Clin Oncol"},{"key":"975_CR52","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","volume":"65","author":"SR Wedge","year":"2005","unstructured":"Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389\u2013400.","journal-title":"Cancer Res"},{"key":"975_CR53","unstructured":"Alberts SR, Morlan BW, Kim GP, et al. NCCTG phase II trial (N044\u00a0J) of AZD2171 for patients with hepatocellular carcinoma (HCC)\u2014interim review of toxicity (abstract 186), Orlando, FL. Presented at 2007 gastrointestinal cancers symposium."},{"issue":"Suppl 2","key":"975_CR54","first-page":"41","volume":"60","author":"JM Wood","year":"2000","unstructured":"Wood JM. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina (B Aires). 2000;60(Suppl 2):41\u20137.","journal-title":"Medicina (B Aires)"},{"key":"975_CR55","first-page":"4015","volume":"62","author":"J Drevs","year":"2002","unstructured":"Drevs J, Muller-Driver R, Wittig C, et al. PTK787\/ZK 222584, a specific vascular endothelial growth factor\u2013receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002;62:4015\u201322.","journal-title":"Cancer Res"},{"issue":"Suppl","key":"975_CR56","first-page":"4134","volume":"23","author":"I Koch","year":"2007","unstructured":"Koch I, Baron A, Roberts S, et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787\/ZK 222584 in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2007;23(Suppl):4134.","journal-title":"J Clin Oncol"},{"key":"975_CR57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/MCB.8.1.25","volume":"8","author":"CR Carlin","year":"1988","unstructured":"Carlin CR, Simon D, Mattison J, Knowles BB. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol. 1988;8:25\u201334.","journal-title":"Mol Cell Biol"},{"key":"975_CR58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1478-3231.1999.tb00056.x","volume":"19","author":"K Harada","year":"1999","unstructured":"Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19:318\u201325.","journal-title":"Liver"},{"key":"975_CR59","first-page":"903","volume":"8","author":"Y Ito","year":"2001","unstructured":"Ito Y, Takeda T, Higashiyama S, et al. Expression of heparin binding epidermal growth factor\u2013like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep. 2001;8:903\u20137.","journal-title":"Oncol Rep"},{"key":"975_CR60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0676.1997.tb00803.x","volume":"17","author":"S Kira","year":"1997","unstructured":"Kira S, Nakanishi T, Suemori S, et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997;17:177\u201382.","journal-title":"Liver"},{"key":"975_CR61","first-page":"1059","volume":"3","author":"A Kiss","year":"1997","unstructured":"Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha\/epidermal growth factor receptor, hepatocyte growth factor\/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res. 1997;3:1059\u201366.","journal-title":"Clin Cancer Res"},{"key":"975_CR62","first-page":"896","volume":"47","author":"YC Yeh","year":"1987","unstructured":"Yeh YC, Tsai JF, Chuang LY, et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987;47:896\u2013901.","journal-title":"Cancer Res"},{"key":"975_CR63","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","volume":"23","author":"PA Philip","year":"2005","unstructured":"Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657\u201363.","journal-title":"J Clin Oncol"},{"key":"975_CR64","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","volume":"110","author":"MB Thomas","year":"2007","unstructured":"Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059\u201367.","journal-title":"Cancer"},{"issue":"Suppl","key":"975_CR65","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/jco.2006.24.18_suppl.4143","volume":"24","author":"PJ O\u2019Dwyer","year":"2006","unstructured":"O\u2019Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group\u2019s Study E1203. J Clin Oncol. 2006;24(Suppl):4143.","journal-title":"J Clin Oncol"},{"key":"975_CR66","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","volume":"64","author":"RK Ramanathan","year":"2009","unstructured":"Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64:777\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"key":"975_CR67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.22829","volume":"110","author":"AX Zhu","year":"2007","unstructured":"Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:581\u20139.","journal-title":"Cancer"},{"issue":"Suppl","key":"975_CR68","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1200\/jco.2007.25.18_suppl.4598","volume":"25","author":"V Gruenwald","year":"2007","unstructured":"Gruenwald V, Wilkens L, Gebel M, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol. 2007;25(Suppl):4598.","journal-title":"J Clin Oncol"},{"key":"975_CR69","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.22532","volume":"109","author":"S Louafi","year":"2007","unstructured":"Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109:1384\u201390.","journal-title":"Cancer"},{"issue":"Suppl","key":"975_CR70","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/jco.2008.26.15_suppl.4604","volume":"26","author":"BH O\u2019Neil","year":"2008","unstructured":"O\u2019Neil BH, Bernard SA, Goldberg RM, et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol. 2008;26(Suppl):4604.","journal-title":"J Clin Oncol"},{"key":"975_CR71","unstructured":"Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972\u201383, 1983.e1\u201311."},{"issue":"Suppl","key":"975_CR72","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/jco.2009.27.15_suppl.4587","volume":"27","author":"L Chen","year":"2009","unstructured":"Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(Suppl):4587.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"975_CR73","doi-asserted-by":"crossref","first-page":"e15574","DOI":"10.1200\/jco.2009.27.15_suppl.e15574","volume":"27","author":"BH O\u2019Neil","year":"2009","unstructured":"O\u2019Neil BH, Williams-Goff LW, Kauh J, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol. 2009;27(Suppl):e15574.","journal-title":"J Clin Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-0975-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-010-0975-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-0975-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:10:42Z","timestamp":1635239442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-010-0975-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1245\/s10434-010-0975-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}